Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
Sponsor: Beijing 302 Hospital
Summary
This is a prospective, open-labled, randomized controlled study to assess efficacy and safety of treatment with Sintilimab (PD-1 antibody) combined Peg-IFNα-2b in CHB patients on stable NAs treatment.
Official title: The Safety and Efficacy of PD-1 Antibody Combined With Pegylated Interferon-α Therapy to Promote the Clinical Cure in Nucleoside (Acid) Analogues-suppressed Chronic Hepatitis B Patients: A Protocol for the Prospective Pilot Study
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2024-05-17
Completion Date
2026-10-08
Last Updated
2026-03-18
Healthy Volunteers
No
Conditions
Interventions
Sintilimab
100mg/10ml/1bottle
Peg-IFNα-2b
180ug/0.5ml/1bottle
NAs
tablets
Locations (1)
the Fifth Medical Center, Chinese PLA General Hospital
Beijing, Beijing Municipality, China